| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- NITD008
-
- $149.00
-
2026-09-10
- CAS:1044589-82-3
- Purity: 98.04%
- Supply Ability: 10g
|
| | 7-Deaza-2'-C-ethynyladenosine Basic information |
| Product Name: | 7-Deaza-2'-C-ethynyladenosine | | Synonyms: | 7-Deaza-2'-C-ethynyladenosine;(2R,3R,4R,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol;7-Deaza-2'-C-acetylene-adenosine;NITD008;7-(2-C-Ethynyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethynyl-β-D-ribofuranosyl)-;NITD008,NITD-008;2’-b-C-Ethynyl?tubercidin | | CAS: | 1044589-82-3 | | MF: | C13H14N4O4 | | MW: | 290.28 | | EINECS: | | | Product Categories: | | | Mol File: | 1044589-82-3.mol |  |
| | 7-Deaza-2'-C-ethynyladenosine Chemical Properties |
| Boiling point | 631.8±55.0 °C(Predicted) | | density | 1+-.0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 10.48±0.70(Predicted) | | form | Solid | | color | White to gray | | InChI | InChI=1/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/s3 | | InChIKey | NKRAIOQPSBRMOV-YFEBQZRFNA-N | | SMILES | C([C@]1([C@@H]([C@@H](CO)O[C@H]1N1C=CC2=C(N=CN=C12)N)O)O)#C |&1:1,2,3,7,r| |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | 7-Deaza-2'-C-ethynyladenosine Usage And Synthesis |
| Uses | NITD008 is an adenosine nucleoside analogue that inhibits proliferation of EV71, which is one of the major causative agents of Hand-Foot-Mouth Disease. | | Biological Activity | NITD008 is a selective inhibitor of flaviviruses including dengue virus (EC50 = 0.64 μM), hepatitis C virus and Zika virus, and has also been shown to inhibit tick-borne flaviviruses in vitro. NITD008 has been reported to inhibit RNA-dependent RNA polymerase (RdRp), an essential protein of RNA viruses. | | in vivo | NITD008 is orally bioavailable and has good pharmacokinetic properties. NITD008 exhibits the best pharmacokinetic parameters when formulated using 6 N of HCl (1.5 equimolar amount), 1 N of NaOH (pH adjusted to 3.5), and 100 mM citrate buffer (pH 3.5). Following i.v. injection, NITD008 has a high volume of distribution (3.71 L/kg) and a low systemic clearance (31.11 mL/min per kg), resulting in a long elimination half-life (t1/2=4.99 h). After p.o. dosing, NITD008 is rapidly absorbed (time of peak plasma concentration=0.5 h), with a maximal plasma concentration of 3 μM and bioavailability of 48%. Treatment of the mice immediately after viral infection with 1 mg/kg of NITD008 does not reduce mortality, but treatment with 3 mg/kg partially protects and treatment with ≥10 mg/kg completely protects the infected mice from death. NITD008 can suppress peak viremia, decrease cytokine elevation, and prevent death[1]. | | storage | Store at -20°C |
| | 7-Deaza-2'-C-ethynyladenosine Preparation Products And Raw materials |
| Raw materials | D-erythro-Pentofuranosid-2-ulose, methyl 3,5-bis-O-[(2,4-dichlorophenyl)methyl]--->4-Chloro-7-(2-C-ethynyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-->(3R,4R,5R)-5-(2,4-dichlorobenzyloxymethyl)-4-(2,4-dichlorobenzyloxy)-3-ethynyl-2-methoxy-tetrahydrofuran-3-ol-->Methyl 3,5-di-O-(2,4-dichlorobenzyl)-D-ribofuranoside |
|